Injectable HIV treatment trial for people with unsuppressed virus
Treatments studied
Part of Infections clinical trials.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have had HIV for at least 12 months.
- Your most recent viral load test must be 200 or higher, even if you've been taking your HIV pills irregularly.
- You must weigh at least 35 kilograms (about 77 pounds).
- You must be willing to get injections in the buttocks and stay in touch with the study team.
- You cannot have known resistance to the study drugs cabotegravir or rilpivirine.
- You cannot be pregnant, planning pregnancy, or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how long an injectable HIV treatment (cabotegravir and rilpivirine) keeps working in people whose virus is already well controlled. It aims to see the real-world experience and how long patients stay on this treatment.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
This trial tests a new injectable HIV treatment (GS-3242 plus lenacapavir) compared to the daily pill Biktarvy for people just starting HIV therapy. If you qualify, you would receive shots every few weeks instead of taking a daily pill.
This study tests whether a combination of two long-acting HIV medications (cabotegravir and rilpivirine), given as shots every month, is safe and works well for pregnant women who are already taking this treatment. It aims to keep the mother's HIV under control and protect the baby.
This study looks at how the long-acting injectable treatment for HIV affects your quality of life and how well it keeps the virus under control. If you've already completed the injections, you'll be asked to complete questionnaires about your experiences.
This trial tests whether switching from daily HIV pills to a long-acting injectable combination (cabotegravir and rilpivirine) is safe and effective for people whose HIV is well controlled. Instead of taking pills every day, you would receive a shot every month or two, which may be more convenient.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.